Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361747 | 0.89 | LMNA (0.56) | RAB9ALMNAROCK2ROCK1 | |
| SCHEMBL3459833 | 0.88 | GAA (0.55) | MAPK14LMNAROCK2KMT2AMEN1 | |
| SCHEMBL13947087 | 0.87 | POLB (0.54) | MAPK14NPC1RAB9ALMNAROCK2 | |
| SCHEMBL4503792 | 0.83 | EPHX2 (0.53) | MAPK14NPC1RAB9AROCK2KMT2A | |
| SCHEMBL678297 | 0.82 | CA2 (0.64) | KMT2A | |
| SCHEMBL6077802 | 0.78 | L3MBTL1 (0.77) | MAPK14L3MBTL1LMNACXCR4KMT2A | |
| SCHEMBL5644578 | 0.78 | GAA (0.52) | NPC1RAB9ALMNAROCK2KMT2A | |
| SCHEMBL3460926 | 0.78 | LMNA (0.64) | RAB9ALMNAROCK2ROCK1 | |
| SCHEMBL13450263 | 0.77 | EPHX2 (0.53) | MAPK14L3MBTL1ROCK2KMT2AMEN1 | |
| SCHEMBL5230740 | 0.77 | HDAC6 (0.72) | NPC1RAB9AL3MBTL1LMNAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | MAPK14 4043/4885NPC1 448/4885RAB9A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.